ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy

Lu, Yiyu; Li, Zhihua; Zhu, Huawei; Zhao, Juan; Xu, Mian; Gu, Weiguang*南方医科大学
Annals of Palliative Medicine2021-12DOI: 10.21037/apm-21-2016
1被引4阅读
引用收藏
分享

摘要

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for patients with advanced non-small-cell lung cancer (NSCLC) harboring classic EGFR mutations. However, resistance to TKIs remains a major clinical challenge. The transformation from adenocarcinoma to small-cell lung cancer (SCLC) is a rare resistance mechanism to EGFR-TKIs. In this article, we report on 2 lung adenocarcinoma patients with EGFR mutations who developed EGFR-TKI resistance. In case one, the patient was initially diagnosed as lung adenocarcinoma with EGFR L858R, RB1 R445*, and TP53 Y205C mutations. EGFR-TKI failed to bring satisfactory curative effect with the emergence of EGFR T790M mutation and MET amplification and finally passed away. In case two, the patient was diagnosed with lung cancer harboring EGFR L747 and TP53 R342* mutations, and EGFR-TKIs brought a progression-free survival for nine months. However, EGFR-TKI resistance was acquired, and adenocarcinoma transformed into a complex of neuroendocrine carcinoma, SCLC, and lung adenocarcinoma, with the emergence of the EGFR L747, TP53 R342*, and RB1 mutations. Follow-up treatments failed to prevent tumor progression, and the patient died These 2 cases expand our understanding of EGFR-TKI resistance, SCLC transformation, and highlight the importance of histopathology and molecular characteristics for therapeutic strategies for transformed SCLC patients.

学科与关键词

关键词
Adenocarcinomaepidermal growth factor receptor-tyrosine kinase inhibitor resistance (EGFR-TKI resistance)transformed small-cell lung cancer (transformed SCLC)TP53 and RB1 mutationscase report
相关
加载中…
  • Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer
    Zhang, Shi-Ling; Zhang, Chan -Yuan; Chen, Yu-Qing; Li, Yu -Fa; Xie, Zhi; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Huang, Jie; Sun, Hao; Zheng, Ming-Ying; Xiao, Fa-Man; Yan, Hong-Hong; Lu, Dan-Xia; Lv, Zhi-Yi; Wu, Yi-Long; Chen, Hua-Jun*; Yang, Jin-Ji*Journal of Thoracic Disease, 2023, 15(9).
  • Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer
    Chen Hua Jun; Mok Tony S; Chen Zhi Hong; Guo Ai Lin; Zhang Xu Chao; Su Jian; Wu Yi Long*Pathology Oncology Research, 2009, 15(4): 651-658.被引 30
  • Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial
    Li, Xiang-Meng; Li, Wen-Feng; Lin, Jun-Tao; Yan, Hong-Hong; Tu, Hai-Yan; Chen, Hua-Jun; Wang, Bin-Chao; Wang, Zhen; Zhou, Qing; Zhang, Xu-Chao; Su, Jian; Chen, Rui-Lian; Wu, Yi-Long*; Yang, Jin-Ji*Clinical Lung Cancer, 2021, 22(2): 100-+.被引 28
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Palliative Medicine
发表日期
2021-12
卷期
第 10 卷, 第 12 期
页码
12886-12893
DOI
10.21037/apm-21-2016
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Foshan Science and Technology Innovation Project (Medical Science and Technology Innovation Platform) [FS0AA-KJ218-1301-0036]

作者

  • L

    Lu, Yiyu (第一作者)

    2 · southern med univ

  • L

    Li, Zhihua

    2 · southern med univ

查看全部 6 位作者收起作者
  • Z

    Zhu, Huawei

    2 · guangxi med univ

  • Z

    Zhao, Juan

  • X

    Xu, Mian

  • G

    Gu, Weiguang (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417